

NEUTRALIZING ANTIBODY FOR IMMUNE REACTIVATION IN CANCER

Technology Offer

F59078

May 2, 2018

Branch

drug development, drug therapy, chronic inflammatory disease

Patent situation

EP patent application filed

Offer

license

Key words

anti-interleukin antibody, cancer

Fraunhofer Institute for Molecular Biology and Applied Ecology IME

Branch for Translational Medicine and Pharmacology
Industriepark Höchst, Gebäude G879
65926 Frankfurt am Main

Contact:

Prof. Dr. Mike J. Parnham
phone: +49 69 8700-25071
michael.parnham@ime.fraunhofer.de

www.ime.fraunhofer.de

Introduction

Most human and experimental tumors educate the immune system to promote rather than suppress tumor development. Therapeutic feasibility of re-activating the tumor-associated immune is demonstrated by immune checkpoint inhibitors, which are neutralizing antibodies directed against immune checkpoint ligands and receptors. However, only a subset of cancer patients benefit from immune checkpoint blockade. Therefore, other strategies to re-activate the tumor-associated immune system alone or in combination with current standard therapy or immunotherapy are required.

Invention

The discovery of an interleukin that is produced in tumors and suppresses the anti-tumor activity of a number of immune cells opens up a new approach to the therapy of cancer. The invention comprises a neutralizing against said interleukin, which is suitable for therapeutic administration. Because of its activity in an experimental tumor model that is resistant to current immune checkpoint therapy (anti-PD-1), the target may be suitable for patients/entities that do not respond to immune checkpoint blockade and for use in combinatorial approaches.

Market Potential

Commercial applications: monotherapy or combination therapy of solid tumors

Development Status

The concept has been demonstrated in gene knockout studies in a mouse model of mammary carcinoma and is currently under investigation in further animal experiments.




Fig 1: Wildtype (WT) and Knockout (KO) mice were bred into the polyoma middle T oncogene (PyMT) mammary carcinoma background and tumor development was monitored. Tumor burden and the number of tumor-free mammary glands (of 10 in total) at an age of 18 weeks are shown. Data are means \pm SEM, n=10, **p<0.01, ***p<0.001.




Fig 2: Wildtype (WT) and Knockout (KO) mice were bred into the PyMT mammary carcinoma background and tumor development was monitored. Major lymphocyte populations infiltrating PyMT tumors and IFN- γ + T cell subsets were determined by flow cytometry at week 18. Data are means \pm SEM, n \geq 6, *p<0.05, ***p<0.001.